ArticleJournal of Alzheimer's disease reports
The role of thyroid hormones in Alzheimer's disease: Associations with cerebrospinal fluid biomarkers and diagnostic performance.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between serum thyroid function indicators and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) pathology, as well as their diagnostic value in dementia differentiation, remains poorly understood in individuals without overt thyroid dysfunction. Objective: The study aims to evaluate the diagnostic value of thyroid hormones in AD. Methods: 225 participants including controls and Alzheimer's disease dementia (ADD), and 322 participants including controls, ADD and other neurodegenerative dementia (NonADD), were selected from cohort 1 and 2, respectively. CSF biomarkers (Aβ Results: In both cohorts, ADD patients exhibited significantly lower levels of FT3, FT4, TT3, and TT4 compared to CN and NonADD groups ( Conclusions: Our findings demonstrate that AD patients exhibit distinct reductions in thyroid hormones (FT3/FT4/TT3/TT4) that correlate strongly with hallmark AD CSF biomarkers and the integration of thyroid indicators with CSF biomarkers significantly improves dementia subtype differentiation, supporting their potential as complementary diagnostic tools in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.